首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1446825

全球筆針市場 - 2024-2031

Global Pen Needles Market - 2024-2031

出版日期: 2024年02月13日 | 出版商:

DataM Intelligence | 英文 206 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球筆針市場達35億美元，預計2031年將達85億美元，2024-2031年預測期間CAGR為11.8%。

隨著越來越多的糖尿病患者普遍使用胰島素，全球筆用針頭市場的需求不斷成長。製造商推出了各種創新功能，例如超細針頭、增強的安全機制和改進的注射技術。

筆式針頭為患者提供了一種便捷的胰島素劑量管理方式，無需任何醫療保健專業人員的幫助。糖尿病自我照護和自我管理趨勢的增加導致對筆針的需求增加。這些進步提高了使用筆針的便利性和安全性，讓患者使用起來更加舒適。

北美是全球筆用針頭市場的成長地區之一，由於其醫療設施的崛起和醫療技術的高度採用，涵蓋了大量的市場區域。該地區的糖尿病患者不斷增加，人口不斷成長推動了市場需求。這些地區的政府採取了各種舉措，以提高人們對筆針市場進步的認知。

筆用針頭市場見證了技術的持續發展。與其他地區相比，亞太地區的成長最快，人口也相對較多。中國、日本和印度的筆用針消費量大幅成長，這些國家的消費量也隨之增加。例如，2022 年 9 月 9 日，全球醫療產業領導者 Terumo India 宣佈為需要注射胰島素的患者推出 FineGlide。

動力學

慢性病盛行率不斷上升

糖尿病、心血管疾病、癌症等慢性病明顯增加。從而增加了筆針市場的需求。這些疾病需要定期用藥，目前通常使用筆式注射器來完成。筆式注射器已成為注射藥物傳輸結構的標準，因為它們易於使用並且可以由受影響的人直接給藥而無需任何外部幫助。

例如，2018年11月14日，HMD為糖尿病患者推出Dispovan筆針胰島素，印度有7,400萬人患有糖尿病。 Hindustan 注射器和醫療設備公司是一次性注射器的領先製造商，並推出了 dispovan 胰島素針頭，這項進步將推動筆式針頭市場的成長。

糖尿病需要定期注射胰島素來維持血糖水平。。智慧胰島素筆提供劑量追蹤、提醒和與智慧型手機應用程式連接等功能，幫助個人保持胰島素治療方案的正常進行。透過促進用藥依從性，智慧胰島素筆有助於更好的疾病管理和改善健康結果。

例如，2023 年 3 月 14 日，智慧胰島素筆是可重複使用的注射筆，可幫助糖尿病患者更輕鬆地管理病情。這些筆與智慧型手機應用程式配合使用，簡化了計算血糖水平、胰島素劑量和膳食量的過程。透過自動化糖尿病管理中涉及的數學，智慧胰島素筆減輕了患有糖尿病症狀的個人所面臨的一些挑戰。

對替代藥物傳輸模式的偏好

一些消費者對針頭有恐懼或厭惡，這導致他們尋求替代的藥物輸送方法。它可以包括胰島素幫浦、吸入器或口服藥物等技術。這些替代方案的可用性可能會影響對筆針的需求，特別是對於優先考慮無針注射的個人而言。

藥物傳遞技術的不斷進步可能為胰島素給藥帶來新的、更方便的選擇。例如，研究人員正在探索微針貼片、植入式裝置和吸入式胰島素製劑的使用。事實證明，替代技術更加方便用戶使用、高效，這將促進市場的成長。

筆式針頭通常比胰島素幫浦等替代藥物輸送設備便宜，但糖尿病管理的整體成本仍然是個人的重要因素。考慮到保險範圍和財務狀況等因素，一些患者會尋求可節省成本或具有更好長期價值的替代方法。

例如，研究人員發現了一種基於植物的胰島素調節系統，其中含有三種胜肽。在植物胰島素中，植物細胞在材料分解成微生物之前保護胰島素免受酸的侵害。研究人員從各個方面探索了這些植物胰島素，例如生產用作胰島素樣化合物的植物蛋白質的基因工程植物。

胰島素注射筆針的局限性

筆針有不同的長度和尺寸，範圍從 4 毫米到 8 毫米。適當的針長取決於體型、皮下脂肪厚度和個人喜好等因素。然而，皮下脂肪較厚的個體可能會發現用較短的針長度有效注射胰島素具有挑戰性，因為胰島素可能無法到達所需的組織深度。

輪換注射部位以避免脂肪肥大並確保胰島素吸收的一致性至關重要。然而，重複使用相同的注射部位可能會導致疤痕組織形成和胰島素吸收不一致。有些人可能會發現由於可用區域有限，很難持續輪換注射部位。

筆式針頭可提供準確的劑量輸送，但劑量測量中仍可能出現人為錯誤。對於個人來說，仔細遵循劑量說明並在注射前仔細檢查劑量至關重要。處理不當或測量不正確可能導致劑量過量或不足，可能影響血糖控制。

安全處理用過的筆針對於防止意外針刺傷害和污染非常重要。適當的處置方案可能並不總是容易獲得，特別是在旅行或在公共場所時。它需要負責任的處置實踐，以確保個人和社區的安全。

Pen needles offer a convenient way for patients to administer their insulin doses without the need for any healthcare professionals. The increase in the trend towards self-care and self-management of diabetes has led to an increase demand for pen needles. The advancements improved the convenience and safety of using pen needles, which makes them more comfortable to use by patients.

North America is among the growing regions in the global pen needles market and covers a large area of the market due to its rise in medical facilities and high adoption of medical technologies. The region has witnessed increasing diabetes patients and a growing population drives the demand for the market. Government in these region adapts various initiatives to create awareness about the advancement that pen needles market offers.

Continuous growth in technology is witnessed in the pen needles market. Asia-Pacific witnessed the highest growth and the population is comparatively high compared to other regions. China, Japan and India witnessed major growth, as consumption of pen needles increased in these countries. For instance, on, 9 Sept 2022, Terumo India a global leader in the medical industry announced the launch of FineGlide for patients who requires insuline injections.

Dynamics

Growing Prevalence of Chronic Diseases

Chronic diseases such as diabetes, cardiovascular disease and cancer significantly increased. Thus increasing demand of pen needle market. The diseases require regular administration of drugs, which is now typically done using pen injectors. Pen injectors have emerged as the norm for injectable drug delivery structures because of the reality that they are easy to apply and may be administered directly by the affected person without any external assistance.

For instance, on 14 Nov 2018, HMD launches Dispovan pen needle insulin for diabetic patients, India witnessed 74 million people suffering from diabetics. Hindustan syringes and medical devices is a leading manufacture of disposable syringes and launched its dispovan insulin needles this advancement will boost the growth of pen needles market.

Diabetes requires regular insulin administration to maintain blood sugar levels. . Smart insulin pens offer features such as dose tracking, reminders and connectivity to smartphone apps, which help individuals stay on track with their insulin regimen. By promoting medication adherence, smart insulin pens contribute to better disease management and improved health outcomes.

For instance, 14 March 2023, on Smart insulin pens are reusable injector pens that help individuals with diabetes manage their condition more easily. The pens work alongside a smartphone app, which simplifies the process of calculating blood sugar levels, insulin dosage and meal sizes. By automating the maths involved in diabetes management, smart insulin pens alleviate some of the challenges faced by individuals experiencing diabetes symptoms.

Preference for Alternative Modes of Drug Delivery

Some consumers have a fear or aversion to needles that leads them to seek alternative methods of drug delivery. It can include technologies such as insulin pumps, inhalers or oral medications. The availability of these alternative options can impact the demand for pen needles, particularly among individuals who prioritize needle-free administration.

Ongoing advancements in drug delivery technologies may introduce new and more convenient options for insulin administration. For example, researchers are exploring the use of microneedle patches, implantable devices and inhalable insulin formulations. The alternative technologies prove to be more user-friendly, efficient these will boost the growth of the market.

Pen needles are generally more affordable than alternative drug delivery devices like insulin pumps, the overall cost of diabetes management can still be a significant factor for individuals. Factors such as insurance coverage and financial situations, some patients go for alternative methods that offer cost savings or better long-term value.

For instance, Researchers found a plant-based insulin-regulated system that contains three peptides. In plant-based insulin, plant cell protect insulines from acids before materials brokes into microbes. Researchers explored these plant based insuline in various aspects such genetically enegineering plants that produce plant-based protein used as insulin-like compound.

Limitations of Pen Needles in Insulin Administration

Pen needles are available in different lengths and sizes, in which ranging starts from 4mm to 8mm. The appropriate needle length depends on factors such as body size, subcutaneous fat thickness and individual preferences. However, individuals with thicker subcutaneous fat may find it challenging to effectively inject insulin with shorter needle lengths, as the insulin may not reach the desired tissue depth.

It is essential to rotate injection sites to avoid lipohypertrophy and ensure consistent insulin absorption. However, using the same injection sites repeatedly can lead to scar tissue formation and inconsistent insulin absorption. Some individuals may find it difficult to consistently rotate injection sites due to limited areas available.

Pen needles provide accurate dose delivery, but human error in dose measurement can still occur. It is crucial for individuals to carefully follow instructions for dosing and to double-check the dosage before injection. Mishandling or incorrect measurement can lead to over- or under-dosing, potentially impacting blood sugar control.

Disposing of used pen needles safely is important to prevent accidental needlestick injuries and contamination. Proper disposal options may not always be readily available, particularly when traveling or in public settings. It requires responsible disposal practices to ensure the safety of individuals and the community.

Segment Analysis

The global pen needles market is segmented based on product, length, therapy, end-user and region.

Rising Safety Pen Needles Demand for Reducing Risk Factors

Safety pen needles are specifically designed to reduce the risk of NSIs and protect both patients and healthcare professionals. The rising number of individuals diagnosed with diabetes has significantly increased the demand for insulin administration devices. As more individuals require insulin therapy, the need for safe and effective needle options becomes critical.

For instance, 27 Jun 2023, Tracey sainsbury discuss that how diabetes is increasing, In 2010 EU directives introduced safety pens. Safety pen needles in insulin administration is crucial for patient safety and the prevention of needlestick injuries. Safety pen needles come in two types: active and passive. Active safety devices show the needle throughout the injection process, requiring the user to manually activate the safety mechanism. Passive safety devices cover the needle before and after the injection, but it may obstruct the visibility of the needle.

Impact of Pen Needles in Hospital

The compact and portable design of pen needles makes them suitable for use in hospitals where mobility and space are often limited. The simplicity of pen needle usage allows for quick and accurate insulin administration, which ensures effective diabetes management for patients. The factors lead to an increase in the growth of needle markets from the hospital sector.

The prevalence of diabetes among patients who were hospitalized witnessed 12% to 26%. A study found that around 2000 patients were diagnosed with hyperglycemia at the time of hospital admission. As insulin pens are cost-effective when compared to traditional injections, so this factor makes them the preferred choice for hospitals.

Geographical Penetration

North American Manages Diabetes with Pen Needle Market

The North American pen needles market has witnessed significant growth because the rise in diabetic patients created an alarming situation in the nation, a report by national diabetes statistics that the diabetes case rise up to 37.3 million. The region has carbonated drinks and foods that have high sugar consumption these factors increase diabetes which leads to an increase in the pen needles market.

For instance, on 28 Dec 2022, research conducted by JAMA open network finds that consumers with diabetes are still experiencing increments in blood sugar levels. For managing insulin therapy patients are commonly using insulin pens that provide more convenient options compared to syringes. Pen needles ensure safety and minimize the risk of infections.

Rapid Growth of Pen Needles Due to Increasing Population

Asia-Pacific has a major growth rate in the consumption of pen needles market. Countries like China, Japan and India witnessed increases in demand due to urbanization and growing population leading to increasing consumption of pen needles in these countries. The region heavily invested in healthcare infrastructure, including medical facilities and services. The enhances the availability and distribution of pen needles that, includes hospitals, clinics and pharmacies.

For instance, on 10 Jul 2023, According to the international diabetes federation the adult population witnessed 10.5% of people having diabetes, due to their living conditions. Around 42.5% of people suffer from diabetes in Delhi and every third person in the house, these factors increase the use of pen needle insulins as they are easy to handle.

COVID-19 Impact Analysis

The pandemic highlighted the importance of chronic health conditions, including diabetes. As individuals with diabetes are considered at higher risk for COVID-19 infection, there has been a growing emphasis on effective diabetes management, including insulin administration using pen needles.

The government-imposed lockdowns and restrictions on the movement and minimized hospitals because of their chance to affected by infection, many individuals have transitioned to home-based care. The shift has led to an increased demand for pen needles, as they are easy to use at home and allow for self-administration of insulin.

The pandemic has disrupted global supply chains, that affect the production and distribution of medical devices, including pen needles. Manufacturers have faced challenges in sourcing raw materials and maintaining production levels that lead to temporary shortages in some regions. The factors affect the growth of the pen needles market.

During a pandemic, there has been an increased focus on infection control and needlestick injuries. The has led to a higher demand for safety pen needles, which incorporate safety mechanisms to reduce the risk of accidental needlestick injuries and enhance patient and healthcare provider safety.

Scope

By Product

Standard Pen Needles
Safety Pen Needles

By Length

4 mm
5 mm
6 mm
8 mm
10 mm
12 mm

By Therapy

Insulin Therapy
Glucagon-Like Peptide-1
Growth Hormone Therapy
Other Therapies

By End-User

Hospitals
Diagnostic Centers
Ambulatory Surgery Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Russia
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Key Developments

On 9 May 2022, Roche Diabetes launches ACCU-Fine pen needles for painless delivery of insulin, which includes a 33G 4mm variant. It have main three key features that ensure comfort to consumer and easy to use.
On 25 May 2022, Owen Mumford announces that the safety pen needle will join unifine safe control brand. The provides safety and control and also protects from needlestick injuries.
On 4 Nov 2022, Walgreens announces its partnership which expands access to complimentary diabetes. Walgreens aims to contribute to better disease management and improved health outcomes for the diabetes community.

Competitive Landscape

The major global players include Becton, Dickinson and Company, Novo Nordisk A/S, B. Braun Melsungen AG, Owen Mumford, Terumo Corporation, Nipro Corporation, Allison Medical, AdvaCare Pharma, Berpu Medical Technology, Trividia Health.

Why Purchase the Report?

To visualize the global pen needles market segmentation based on product, length, therapy, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Pen Needles market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global pen needles market report would provide approximately 69 tables, 71 figures and 206 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Lenght
3.3. Snippet by Therapy
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing Prevalence of Chronic Diseases
  - 4.1.1.2. Preference for Alternative Modes of Drug Delivery
- 4.1.2. Restraints
  - 4.1.2.1. Limitations of Pen Needles in Insulin Administration
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Standard Pen Needles *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Safety Pen Needles

8. By Length

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 8.1.2. Market Attractiveness Index, By Length
8.2. 4 mm*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. 5 mm
8.4. 6 mm
8.5. 8 mm
8.6. 10 mm
8.7. 12 mm

9. By Therapy

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 9.1.2. Market Attractiveness Index, By Therapy
9.2. Insulin Therapy *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Glucagon-Like Peptide-1
9.4. Growth Hormone Therapy
9.5. Other Therapies

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Ambulatory Surgery Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Russia
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Length
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Becton, Dickinson and Company*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Novo Nordisk A/S
13.3. B. Braun Melsungen AG
13.4. Owen Mumford
13.5. Terumo Corporation
13.6. Nipro Corporation
13.7. Allison Medical
13.8. AdvaCare Pharma
13.9. Berpu Medical Technology
13.10. Trividia Health

LIST NOT EXHAUSTIVE